{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:37:19Z","timestamp":1787495839378,"version":"build-2736575974"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773375"],"award-info":[{"award-number":["81773375"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802801"],"award-info":[{"award-number":["81802801"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2019ZX09201001"],"award-info":[{"award-number":["2019ZX09201001"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    Peroxisome proliferator-activated receptor \u03b1\/\u03b4 (PPAR \u03b1\/\u03b4), regulating glucolipid metabolism and immune inflammation, has been identified as an effective therapeutic target in non-alcoholic steatohepatitis (NASH). Dual PPAR \u03b1\/\u03b4 agonist, such as GFT505 (also known as elafibranor), demonstrated potential therapeutic effect for NASH in clinical trials. To profile the regulatory network of PPAR \u03b1\/\u03b4 agonist in NASH, the choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) induced NASH model was used to test the pharmacodynamics and transcriptome regulation of GFT505 in this study. The results showed that GFT505 ameliorated hepatic steatosis, inflammation and fibrosis in CDAHFD mice model. RNA-sequencing yielded 3995 up-regulated and 3576 down-regulated genes with GFT505 treatment. And the most significant differentialy expressed genes involved in glucolipid metabolism (\n                    <jats:italic>Ppar\u03b1<\/jats:italic>\n                    ,\n                    <jats:italic>Acox1<\/jats:italic>\n                    ,\n                    <jats:italic>Cpt1b<\/jats:italic>\n                    ,\n                    <jats:italic>Fabp4<\/jats:italic>\n                    ,\n                    <jats:italic>Ehhadh<\/jats:italic>\n                    ,\n                    <jats:italic>Fabp3<\/jats:italic>\n                    ), inflammation (\n                    <jats:italic>Ccl6<\/jats:italic>\n                    ,\n                    <jats:italic>Ccl9<\/jats:italic>\n                    ,\n                    <jats:italic>Cxcl14<\/jats:italic>\n                    ) and fibrosis (\n                    <jats:italic>Timp1<\/jats:italic>\n                    ,\n                    <jats:italic>Lamc3<\/jats:italic>\n                    ,\n                    <jats:italic>Timp2<\/jats:italic>\n                    ,\n                    <jats:italic>Col3a1<\/jats:italic>\n                    ,\n                    <jats:italic>Col1a2<\/jats:italic>\n                    ,\n                    <jats:italic>Col1a1<\/jats:italic>\n                    ,\n                    <jats:italic>Hapln4<\/jats:italic>\n                    ,\n                    <jats:italic>Timp3<\/jats:italic>\n                    ,\n                    <jats:italic>Pik3r5<\/jats:italic>\n                    ,\n                    <jats:italic>Pdgf\u03b1<\/jats:italic>\n                    ,\n                    <jats:italic>Pdgf\u03b2<\/jats:italic>\n                    ,\n                    <jats:italic>Tgf\u03b21<\/jats:italic>\n                    ,\n                    <jats:italic>Tgf\u03b22<\/jats:italic>\n                    ) were confirmed by RT-qPCR. The down-regulated genes were enriched in cytokine-cytokine receptor interaction pathway and ECM-receptor interaction pathway, while the up-regulated genes were enriched in PPAR signaling pathway and fatty acid degradation pathway. This study provides clues and basis for further understanding on the mechanism of PPAR \u03b1\/\u03b4 agonist on NASH.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0243911","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T15:42:56Z","timestamp":1608133376000},"page":"e0243911","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["The pharmacodynamic and differential gene expression analysis of PPAR \u03b1\/\u03b4 agonist GFT505 in CDAHFD-induced NASH model"],"prefix":"10.1371","volume":"15","author":[{"given":"Linfu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinliang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2097-6978","authenticated-orcid":true,"given":"Yuqin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"issue":"6","key":"pone.0243911.ref001","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Z Younossi","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"pone.0243911.ref002","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","article-title":"Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study","volume":"140","author":"CD Williams","year":"2011","journal-title":"Gastroenterology"},{"issue":"1","key":"pone.0243911.ref003","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/gast.2002.34168","article-title":"Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma","volume":"123","author":"E Bugianesi","year":"2002","journal-title":"Gastroenterology"},{"key":"pone.0243911.ref004","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-981-10-8684-7_3","article-title":"Pathogenesis of NASH: how metabolic complications of overnutrition favour lipotoxicity and pro-inflammatory fatty liver disease","volume":"1061","author":"GC Farrell","year":"2018","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"pone.0243911.ref005","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jhep.2018.10.023","article-title":"Inflammatory pathways in alcoholic steatohepatitis","volume":"70","author":"B Gao","year":"2019","journal-title":"J Hepatol"},{"issue":"1","key":"pone.0243911.ref006","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1186\/s12864-018-4834-3","article-title":"The whole transcriptome effects of the PPARalpha agonist fenofibrate on livers of hepatocyte humanized mice","volume":"19","author":"MA De lRR","year":"2018","journal-title":"BMC Genomics"},{"issue":"7","key":"pone.0243911.ref007","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s11745-016-4160-y","article-title":"Free fatty acids increase intracellular lipid accumulation and oxidative stress by modulating PPARalpha and SREBP-1c in L-02 cells","volume":"51","author":"S Qin","year":"2016","journal-title":"Lipids"},{"issue":"1\u20132","key":"pone.0243911.ref008","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejphar.2006.02.028","article-title":"Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet","volume":"536","author":"T Nagasawa","year":"2006","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"pone.0243911.ref009","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"V Ratziu","year":"2016","journal-title":"Gastroenterology"},{"issue":"10","key":"pone.0243911.ref010","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.2337\/dc12-2012","article-title":"Dual peroxisome proliferator-activated receptor alpha\/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects","volume":"36","author":"B Cariou","year":"2013","journal-title":"Diabetes Care"},{"issue":"9","key":"pone.0243911.ref011","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.2337\/dc11-0093","article-title":"Effects of the new dual PPAR-\u03b1 and -\u03b4 agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism","volume":"34","author":"B Cariou","year":"2011","journal-title":"Diabetes Care"},{"issue":"6","key":"pone.0243911.ref012","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/hep.26461","article-title":"Hepatoprotective effects of the dual peroxisome proliferator-activated receptor -\u03b1 and \u2013\u03b4 agonist, GFT505, in rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"58","author":"B Staels","year":"2013","journal-title":"Hepatology"},{"issue":"5","key":"pone.0243911.ref013","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/jat.3587","article-title":"Comparative RNA-Seq transcriptome analysis on silica induced pulmonary inflammation and fibrosis in mice silicosis model","volume":"38","author":"J Chen","year":"2018","journal-title":"J Appl Toxicol"},{"issue":"12","key":"pone.0243911.ref014","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00210-019-01703-5","article-title":"The dual PPAR-\u03b1\/\u03b3 agonist saroglitazar ameliorates thioacetamide-induced liver fibrosis in rats through regulating leptin","volume":"392","author":"MN Makled","year":"2019","journal-title":"Naunyn-Schmiedeberg\u2019s Archives of Pharmacology"},{"issue":"3","key":"pone.0243911.ref015","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1139\/bcb-2016-0142","article-title":"Diosmin attenuates radiation- induced hepatic fibrosis via boosting PPAR-\u03b3 expression and hampering miR-17-5p activated canonical Wnt \u03b2-catenin signaling","volume":"95","author":"H HF","year":"2017","journal-title":"Biochem Cell Bio"},{"issue":"1","key":"pone.0243911.ref016","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1124\/jpet.118.255216","article-title":"RLA8-A new and highly effective quadruple PPAR-\u03b1\/\u03b3\/\u03b4 and GPR40 agonist to reverse nonalcoholic steatohepatitis and fibrosis","volume":"369","author":"MH Li","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"pone.0243911.ref017","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/gutjnl-2016-312431","article-title":"Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease","volume":"66","author":"Y Rotman","year":"2017","journal-title":"Gut"},{"key":"pone.0243911.ref018","first-page":"1","article-title":"Rodent models of nonalcoholic fatty liver disease","author":"F Zhong","year":"2019","journal-title":"Digestion"},{"key":"pone.0243911.ref019","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/jgh.12244","article-title":"Role of diet and nutritional management in non-alcoholic fatty liver disease","volume":"28","author":"JG Fan","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"pone.0243911.ref020","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/hep.20877","article-title":"Steatohepatitis induced by intragastric overfeeding in mice","volume":"42","author":"QG Deng","year":"2005","journal-title":"Hepatology"},{"issue":"24","key":"pone.0243911.ref021","doi-asserted-by":"crossref","first-page":"18528","DOI":"10.1074\/jbc.M109.099333","article-title":"Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-L-methionine and glutathione","volume":"285","author":"F Caballero","year":"2010","journal-title":"J Biol Chem"},{"issue":"1","key":"pone.0243911.ref022","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2003.09.020","article-title":"The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance","volume":"40","author":"ME Rinella","year":"2004","journal-title":"J Hepatol"},{"issue":"10","key":"pone.0243911.ref023","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1194\/jlr.M600198-JLR200","article-title":"Mice fed a lipogenic methionine-choline-deficient diet develop hypermetabolism coincident with hepatic suppression of SCD-1","volume":"47","author":"G Rizki","year":"2006","journal-title":"J Lipid Res"},{"key":"pone.0243911.ref024","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/iep.12008","article-title":"An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis","volume":"94","author":"M Matsumoto","year":"2013","journal-title":"Int Journal Exp Pathol"},{"issue":"9","key":"pone.0243911.ref025","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/s41374-018-0074-z","article-title":"Characterization of a murine nonalcoholic steatohepatitis model induced by high fat high calorie diet plus fructose and glucose in drinking water","volume":"98","author":"XJ Liu","year":"2018","journal-title":"Lab Invest"},{"issue":"2","key":"pone.0243911.ref026","article-title":"White pitaya (hylocereus undatus) juice attenuates insulin resistance and hepatic steatosis in diet-induced obese mice","volume":"11","author":"HZ Song","year":"2016","journal-title":"Plos One"},{"issue":"1","key":"pone.0243911.ref027","doi-asserted-by":"crossref","first-page":"13362","DOI":"10.1038\/s41598-017-13835-w","article-title":"HIV-1 viral protein R (Vpr) induces fatty liver in mice via LXR\u03b1 and PPAR\u03b1 dysregulation: implications for HIV-specific pathogenesis of NAFLD","volume":"7","author":"N Agarwal","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"pone.0243911.ref028","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"M Pawlak","year":"2015","journal-title":"J Hepatol"},{"key":"pone.0243911.ref029","first-page":"1","article-title":"Beneficial effects of korean red ginseng in the progression of non-alcoholic steatohepatitis via FABP4 modulation","author":"H Jeong","year":"2018","journal-title":"Am J Chin Med"},{"issue":"11","key":"pone.0243911.ref030","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3390\/v11111020","article-title":"Emerging role of LY6E in virus-host interactions","volume":"11","author":"J Yu","year":"2019","journal-title":"Viruses"},{"issue":"1","key":"pone.0243911.ref031","doi-asserted-by":"crossref","first-page":"13670","DOI":"10.1038\/s41598-018-32011-2","article-title":"Interleukin-17D and Nrf2 mediate initial innate immune cell recruitment and restrict MCMV infection","volume":"8","author":"R Seelige","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0243911.ref032","doi-asserted-by":"crossref","first-page":"F238","DOI":"10.1152\/ajprenal.00313.2019","article-title":"IL-17A activated by toll-like receptor 9 contributes to development of septic acute 2 kidney injury","volume":"318","author":"Y Naito","year":"2019","journal-title":"Am J Physiol-Renal"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0243911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T15:43:25Z","timestamp":1608133405000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0243911"}},"subtitle":[],"editor":[{"given":"Jonathan M","family":"Peterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0243911","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,16]]}}}